$Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial$

Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

Summary FRAX ® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of FR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Osteoporosis international 2020-10, Vol.31 (10), p.1935-1942
Hauptverfasser:	Body, J.-J., Marin, F., Kendler, D.L., Zerbini, C.A.F., López-Romero, P., Möricke, R., Casado, E., Fahrleitner-Pammer, A., Stepan, J.J., Lespessailles, E., Minisola, S., Geusens, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Bisphosphonates Bone Density Bone Density Conservation Agents - therapeutic use Clinical trials Double-Blind Method Endocrinology Female Forearm Fractures Human health and pathology Humans Humerus Life Sciences Medicine Medicine & Public Health Original Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporotic Fractures - epidemiology Osteoporotic Fractures - etiology Osteoporotic Fractures - prevention & control Parathyroid hormone Patients Post-menopause Rheumatology Rhumatology and musculoskeletal system Risedronic acid Risedronic Acid - therapeutic use Risk assessment Statistical analysis Teriparatide - therapeutic use Trauma Vertebrae
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!